Aeterna Zentaris signs license agreement for potential Zoptrex marketing
Aeterna Zentaris and Specialised Therapeutics Asia, or STA, announced the signing of an exclusive license agreement for the company's lead investigational anti-cancer compound, Zoptrex, for the territories of Australia and New Zealand. Zoptrex, a novel synthetic peptide carrier linked to doxorubicin, is currently undergoing a fully-enrolled Phase 3 clinical trial to evaluate the compound in endometrial cancer. The company expects to complete the Phase 3 clinical trial in 2016 and, if the results of the trial warrant doing so, to submit a new drug application for Zoptrex to the U.S. FDA in the first half of 2017. Zoptrex is the company's proposed tradename for zoptarelin doxorubicin. Under the terms of the License Agreement, Aeterna Zentaris will be entitled to receive a non-refundable upfront payment in consideration for the license to STA of the company's intellectual property related to Zoptrex and the grant to STA of the right to commercialize Zoptrex in the Territory. STA has also agreed to make additional payments to the company upon achieving certain pre-established regulatory and commercial milestones, as well as double-digit royalties on future net sales of Zoptrex in the Territory. STA will be responsible for the development, registration, reimbursement and commercialization of the product in the Territory. The company and STA have also entered into a supply agreement, pursuant to which the company will supply Zoptrex to STA for the duration of the license agreement.